Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 188011, Ly
2. 2' Deoxy 2' Difluorocytidine
3. 2' Deoxy 2',2'' Difluorocytidine 5' O Monophosphate
4. 2',2'-dfdc
5. 2',2'-difluoro-2'-deoxycytidine
6. 2',2'-difluorodeoxycytidine
7. 2'-deoxy-2',2''-difluorocytidine-5'-o-monophosphate
8. 2'-deoxy-2'-difluorocytidine
9. Dfdcyd
10. Gemcitabine
11. Gemcitabine, (alpha-d-threo-pentofuranosyl)-isomer
12. Gemcitabine, (beta-d-threo-pentafuranosyl)-isomer
13. Gemcitabine, (d-threo-pentafuranosyl)-isomer
14. Gemicitabine
15. Gemzar
16. Hydrochloride, Gemcitabine
17. Ly 188011
18. Ly-188011
1. Gemcitabine Hcl
2. 122111-03-9
3. Gemzar
4. Ly188011 Hydrochloride
5. Gemcitabine (hydrochloride)
6. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride
7. Cytidine, 2'-deoxy-2',2'-difluoro-, Monohydrochloride
8. Dfdc
9. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one Hydrochloride
10. Gemcitabine (as Hydrochloride)
11. U347pv74il
12. Chebi:31647
13. 2',2'-difluoro-2'-deoxycytidine Hydrochloride
14. Ly-188011 Hydrochloride
15. Ly-188011
16. 122111-03-9 (hcl)
17. Dsstox_cid_27827
18. Dsstox_rid_82590
19. Dsstox_gsid_47849
20. 2'-deoxy-2',2'-difluorocytidine Hydrochloride
21. 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
22. Dizirconium Silicide
23. Cas-122111-03-9
24. Gemcitabine Hydrochloride [usan]
25. Gemcitabine Hcl (gemzar)
26. Ly 188011
27. Unii-u347pv74il
28. Mfcd01735988
29. Ncgc00168784-01
30. Gemzar (tn)
31. Infugem
32. Gemcitabine Hydrochloride [usan:usp]
33. Inno-d07001
34. Schembl4366
35. Chembl1637
36. Ly 188011 Hydrochloride
37. Mls003915643
38. Gemcitabine Hydrochloride,(s)
39. Dtxsid3047849
40. Ex-a837
41. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride (beta-isomer)
42. Act06731
43. Hy-b0003
44. Ly-188011 . Hcl
45. Tox21_112644
46. Bdbm50247964
47. Gemcitabine Hydrochloride (jan/usp)
48. S1149
49. Gemcitabine Hydrochloride [mi]
50. Akos015999730
51. Tox21_112644_1
52. Ccg-267459
53. Cs-0755
54. Gemcitabine Hcl (gemzar,ly188011)
55. Gemcitabine Hydrochloride [jan]
56. 2'-deoxy-2',2'-difluorocytidine Hcl
57. Gemcitabine Hydrochloride [mart.]
58. Gemcitabine Hydrochloride [vandf]
59. Ncgc00168784-03
60. As-13656
61. Bg164501
62. Gemcitabine Hydrochloride [usp-rs]
63. Gemcitabine Hydrochloride [who-dd]
64. Smr000469146
65. Gemcitabine Hydrochloride, >=98% (hplc)
66. Gemcitabine Hydrochloride,gemzar, Ly-188011
67. D01155
68. Gemcitabine Hydrochloride [ep Monograph]
69. Gemcitabine Hydrochloride [orange Book]
70. 2'-deoxy-2',2'-difluorocytidine, Hydrochloride
71. Gemcitabine Hydrochloride [usp Monograph]
72. 111g039
73. W-60402
74. (+)-2'-deoxy-2',2'-difluorocytidine Hydrochloride
75. J-700175
76. Q27114559
77. 2'-deoxy-2',2'-difluorocytidine Monohydrochloride (.beta.-isomer)
78. Gemcitabine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
79. Gemcitabine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
80. (2'r,4'r,5'r)-4-amino-1-(3,3-difluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyridin-2-one Hydrochloride
81. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-one Hydrochloride
82. 4-amino-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-onehydrochloride
1. Gemcitabine Free Base
Molecular Weight | 299.66 g/mol |
---|---|
Molecular Formula | C9H12ClF2N3O4 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 299.0484399 g/mol |
Monoisotopic Mass | 299.0484399 g/mol |
Topological Polar Surface Area | 108 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 426 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Gemcitabine hydrochloride |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 200mg base/vial; 1gm/26.3ml (38mg/ml); 2gm/52.6ml (38mg/ml); 200mg/5.26ml (38mg/ml); eq 1gm base/vial |
Market Status | Prescription |
Company | Hospira; Jiangsu Hansoh Pharm; Fresenius Kabi Oncol; Accord Hlthcare; Cipla; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Teva Pharms; Fresenius Kabi Usa; Onco Therapies; Hameln Rds Gmbh; Luitpold; Sagent Pharms; Dr Reddys Labs |
2 of 4 | |
---|---|
Drug Name | Gemzar |
PubMed Health | Gemcitabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 200mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Lilly |
3 of 4 | |
---|---|
Drug Name | Gemcitabine hydrochloride |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 200mg base/vial; 1gm/26.3ml (38mg/ml); 2gm/52.6ml (38mg/ml); 200mg/5.26ml (38mg/ml); eq 1gm base/vial |
Market Status | Prescription |
Company | Hospira; Jiangsu Hansoh Pharm; Fresenius Kabi Oncol; Accord Hlthcare; Cipla; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Teva Pharms; Fresenius Kabi Usa; Onco Therapies; Hameln Rds Gmbh; Luitpold; Sagent Pharms; Dr Reddys Labs |
4 of 4 | |
---|---|
Drug Name | Gemzar |
PubMed Health | Gemcitabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2-deoxy-2,2-difluorocytidine monohydrochloride (-isomer). The structural formula is as follows: The empirical... |
Active Ingredient | Gemcitabine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 200mg base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | Lilly |
Treatment of urothelial carcinoma
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Loqtorzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SEC Recommends Approval to Dr Reddy's to Import and Market Anti-cancer Drug Toripalimab
Details : Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent lo...
Brand Name : Loqtorzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 18, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: IMM-1-104
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2024
Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.
Brand Name : IMM-1-104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2024
Details:
Pamrevlumab is a potential first-in-class anti-CTGF fully human monoclonal antibody being developed by FibroGen to inhibit the activity of CTGF, in patients with pancreatic cancer.
Lead Product(s): Pamrevlumab,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: FG-3019
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2024
Lead Product(s) : Pamrevlumab,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FibroGen Announces Topline Results from Pamrevlumab Pancreatic Cancer Studies and Update
Details : Pamrevlumab is a potential first-in-class anti-CTGF fully human monoclonal antibody being developed by FibroGen to inhibit the activity of CTGF, in patients with pancreatic cancer.
Brand Name : FG-3019
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 30, 2024
Details:
Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Loqtorzi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Junshi Biosciences Receives Positive EMA CHMP Opinion for Toripalimab
Details : Loqtorzi (toripalimab) is an approved anti-PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic nasopharyngeal carcinoma.
Brand Name : Loqtorzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 26, 2024
Details:
RenovoGem (gemcitabine) is a drug device combination which is bein developed in patients with locally advanced pancreatic cancer.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Brand Name: RenovoGem
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UNMC Launches Enrollment for RenovoRx’s Phase III TIGeR-PaC Clinical Trial
Details : RenovoGem (gemcitabine) is a drug device combination which is bein developed in patients with locally advanced pancreatic cancer.
Brand Name : RenovoGem
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with muscle-invasive bladder cancer.
Lead Product(s): Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Durvalumab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMFINZI® Shows Significant Improvement in Survival for Bladder Cancer in NIAGARA Trial
Details : Imfinzi (durvalumab) is an anti-PD-L1 human monoclonal antibody. It is being evaluated for the treatment of patients with muscle-invasive bladder cancer.
Brand Name : Imfinzi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor, being evaluated in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Brand Name: SBP-101
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Lead Product(s) : Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Panbela Reports Third Safety Review Recommending Continuation of ASPIRE Trial
Details : SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor, being evaluated in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Brand Name : SBP-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2024
Details:
Cosela (trilaciclib) is being evaluated in combination with chemotherapeutic drugs gemcitabine and carboplatin in patients with metastatic metastatic triple negative breast cancer.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Brand Name: Cosela
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Lead Product(s) : Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in mTNBC Patients
Details : Cosela (trilaciclib) is being evaluated in combination with chemotherapeutic drugs gemcitabine and carboplatin in patients with metastatic metastatic triple negative breast cancer.
Brand Name : Cosela
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2024
Details:
IMM-101, is a broad-spectrum immunomodulatory agent investigated in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer.
Lead Product(s): IMM-101,Gemcitabine,Pembrolizumab
Therapeutic Area: Oncology Brand Name: IMM-101
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Precision-Panc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Lead Product(s) : IMM-101,Gemcitabine,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Precision-Panc
Deal Size : Not Applicable
Deal Type : Not Applicable
Precision-Panc Launches PRIMUS-006 Study
Details : IMM-101, is a broad-spectrum immunomodulatory agent investigated in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer.
Brand Name : IMM-101
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 18, 2024
Details:
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor, which is approved in combination with cisplatin and gemcitabine, for the patients with unresectable or metastatic urothelial carcinoma.
Lead Product(s): Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Brand Name: Opdivo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2024
Lead Product(s) : Nivolumab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BMS Receives EU Approval for Opdivo® with Cisplatin and Gemcitabine in Urothelial Cancer
Details : Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor, which is approved in combination with cisplatin and gemcitabine, for the patients with unresectable or metastatic urothelial carcinoma.
Brand Name : Opdivo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 29, 2024
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?